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Abstract
Objective: This study aimed to investigate the association between Photodynamic Diagnosis (PDD) with hexa-
minolevulinate (HAL) and the rate of complete resection and disease persistence at first follow-up cystoscopy for non-
muscle-invasive bladder cancer (NMIBC) in UK real-world practice.
Methods: Audit data were pooled from six UK centres where HAL PDD was used in patients with a new NMIBC 
diagnosis undergoing transurethral resection of bladder tumours (TURBT) since 2008. Patients received adjunctive intra-
vesical therapy and surveillance in line with European and UK guidelines, including early re-resection in high-grade NMIBC.
Results: PDD-assisted TURBT was done in 837 patients with new NMIBC. The detrusor muscle was present in 69.4% of 
cases. At early re-TURBT in 207 high-risk patients, 13.0% had residual disease. Multifocal disease was the most significant 
factor in increasing the rate of residual disease (odds ratio excluding cases of CIS=4.1; 95% confidence interval 1.5–11.3). 
The recurrence rate at first follow-up cystoscopy (RRFFC) was 10.6% (8.9% in patients with complete initial TURBT). In 
the historical cohort undergoing good-quality white-light TURBT, RRFFC was 31%; 40.5% of high-risk patients had residual 
disease at early re-TURBT.
Conclusion: HAL PDD may increase the rates of complete resection, reducing the risk of early recurrence and the 
need for routine re-resection in high-grade NMIBC.
Level of evidence: 2b.
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Introduction
Transurethral resection of bladder tumours (TURBT) is 
the mainstay of treatment for non-muscle-invasive bladder 
cancer (NMIBC). However, although the intention of such 
treatment is curative, recurrence rates are high, necessitat-
ing regular and often prolonged follow-up.1 As a result, 
bladder cancer places a heavy and long-term burden on 
health-care resources and on patients.2
The European Association of Urology recommends 
repeat TURBT after two to six weeks for patients at high 
risk of recurrence.1 For example, the prevalence of 
tumour persistence in patients with Ta and T1 tumours 
has been reported at approximately 39–47%.3,4 However, 
a blanket policy of early re-resection is burdensome for 
service providers and patients alike. We believe that the 
rate of residual disease after initial resection could be 
reduced by emphasising better-quality initial TURBT, 
thus obviating the need for default early re-resection in 
every high-risk case.
Clinical trials and real-world experience show that use 
of photodynamic diagnosis (PDD; also known as fluores-
cence cystoscopy) increases detection of tumours, espe-
cially carcinoma in situ (CIS), compared to white-light 
cystoscopy (WLC) alone and improves clearance of 
tumour margins.5–7 Long-term follow-up of the largest 
randomised clinical trial of hexaminolevulinate (HAL) 
indicates that this improved detection translates into a 
clinically significant reduction in recurrence-free survival 
(p=0.04),8 with a trend towards reduced progression rates 
compared to WLC.9
To date, there is limited evidence on the role of HAL 
PDD in reducing residual disease at early re-TURBT, with 
one single-centre study (N=446) indicating a significant 
reduction in recurrence rate at the six-week re-TURBT 
from 31.2% with WLC to 11.1% with PDD (p=0.0001).10 
The objective of the present analysis was to describe 
residual disease rates and recurrence in a large population 
of patients, using pooled audit data from an ongoing col-
laboration between urological teams at seven centres 
across the UK.
Methods
Data were collected as an audit of outcomes/quality pro-
spectively (Edinburgh) or retrospectively (Barnet, 
Middlesbrough, Exeter, Bridgend and Basingstoke) on all 
new NMIBC patients receiving HAL PDD-guided cystos-
copy or TURB-T from 2008 until May 2011 in the partici-
pating centres, with analysis focusing on risk of residual 
disease at early re-TURBT in patients with high-grade 
NMIBC, recurrence rate at the first follow-up cystoscopy 
(RRFFC) and comparison of the above end points between 
TURBT guided by PDD (PDD-TURBT) and TURBT per-
formed under white-light (WL-TURBT) in a historical 
cohort from Edinburgh.
Medical procedures
Mitomycin C was given to all patients within 24 hours of 
initial resection in most centres unless contraindicated or if 
it was felt inappropriate by the clinician. Further intra-ves-
ical instillation of mitomycin C or bacille Calmette–Guérin 
(BCG) in line with European and UK guidelines was 
dependent on local policy following discussion at the mul-
tidisciplinary meeting. None of the patients received BCG 
prior to the early re-TURBT, and a six-week course of 
mitomycin C was used in only one centre for 16 patients 
with intermediate-risk NMIBC.
In patients with high-grade NMIBC, re-TURBT was per-
formed within six weeks of initial TURBT, and cystoscopy 
+biopsy was performed at three months where re-TURBT 
was felt inappropriate by the local team. High-grade NMIBC 
was defined according to the World Health Organization 
1973 and 2004 classifications as high-grade (anaplastic) 
CIS or papillary urothelial carcinoma (PUC). All patients 
with low- to intermediate-risk NMIBC had the first check 
cystoscopy at three months. Completeness of resection post 
TURBT was assessed visually by the consultant carrying 
out the TURBT or by the supervising consultant if the 
TURBT procedure was carried out by a trainee.
Data collection
To ensure uniform data reporting and minimise bias across 
centres, a standardised pro forma based on bladder map-
ping and tumour features (Figure 1) was used to collect 
specific information, including tumour size, number, 
appearance, completeness of resection, use of mitomycin 
C, clinical stage, presence or absence of detrusor muscle in 
the resection specimen and surgeon experience. Residual 
or recurrent disease was defined as histologically proven 
cancer on resection or biopsy. RRFFC was used as a meas-
ure of the quality of TURBT and therefore included results 
from early re-TURBT for high-grade NMIBC, as well as 
data from the three-month follow-up visit in patients with 
low- or intermediate-risk disease.
As this was a single-arm analysis of routinely collected 
data, no sample size calculation was performed. Multivariate 
logistic regression analysis was carried out where appropri-
ate. Statistical analysis was carried out using SPSS for 
Windows v16 (SPSS, Inc., Chicago, IL). To provide a real-
world context in which to assess the impact of PDD, early 
recurrence rates in patients undergoing PDD-TURBT were 
also compared informally to those in a control group of 
patients from one of the centres (Western General 
Hospital, Edinburgh, UK) who had received good-quality 
WL-TURBT (GQ-WLTURBT) involving (a) cystoscopic 
mapping using a bladder diagram, (b) documented complete 
resection of the tumour, (c) resection performed or super-
vised by an experienced surgeon (consultant or trainee at 
year 5 or beyond), (d) presence of detrusor muscle in the 
specimen and (e) mitomycin C instillation within 24 hours 
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after the resection. Detailed findings for this control group 
have been published previously.6,11
Results
In total, PDD-assisted surgery was carried out in 1127 
patients, of whom 1008 had new bladder cancer of any 
stage (including stages T2–T4). The present analysis 
focuses on the 837 patients with new NMIBC, comprising 
295 from Edinburgh, 192 from Basingstoke, 163 from 
Barnet, 85 from Middlesbrough, 64 from Exeter and 38 
from Bridgend. The mean age of patients with newly diag-
nosed NMIBC was 70.5 years. Baseline demographics are 
described in Table 1.
Figure 1. Bladder cancer operation notes/pro forma v3.
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Table 1. Patient demographics, tumour characteristics and surgeon category at first transurethral resection of the bladder for all 
patients with newly diagnosed NMIBC.
Characteristics Patients, n (%)
Patients with new NMIBC 837
NMIBC without tumour features recorded 192 (22.9)
Tumour size <5 mm 145 (22.5)
 5–10 mm 139 (26.8)
 10–30 mm 173 (21.6)
 >30 mm 188 (29.2)
Tumour multiplicity Single 358 (63.9)
 2 90 (13.9)
 3 43 (6.7)
 >3 154 (23.9)
Tumour appearance Papillary 518 (80.3)
 Solid 28 (4.3)
 Mixed papillary and solid 86 (13.3)
 Flat lesion (red patch or carpet like) 13 (2.0)
Primary grade (World Health 
Organization 1973 and 2004)
G1 (including PUNLMP) 233 (27.8)
 G2 (low-gradea PUC) 315 (37.6)
 G3 (includes high-gradeb G2) 242 (28.9)
 G3+CIS 22 (2.6)
 Primary CIS 25 (2.9)
Primary stage Ta 593 (70.7)
 T1 191 (22.8)
 Ta/T1+Tis 21 (2.5)
 Tis 25 (2.9)
 Tx 7 (0.8)
Complete resection Yes 759 (90.7)
 No 49 (5.9)
 Biopsy and diathermy 5 (0.6)
 Unsure 22 (2.6)
Detrusor muscle in specimen Present 581 (69.4)
 Absent 233 (27.8)
 Not sure 23 (2.8)
Surgeon category Senior (consultant or trainee ⩾5 
years)
694 (82.9)
 Junior (trainee <5 years) 117 (13.9)
 Unknown 26 (3.1)
aLow-grade PUC defined as a neoplasm of urothelium lining papillary fronds which shows an orderly appearance but easily recognisable variations in 
architecture and cytologic features.
bHigh-grade G2 (PUC) defined as a neoplasm of urothelium lining papillary fronds which shows a predominant pattern of disorder with moderate-
to-marked architectural and cytologic atypia.
NMIBC: non-muscle-invasive bladder cancer; CIS: carcinoma in situ; PUC: papillary urothelial carcinoma; PUNLMP: papillary urothelial neoplasm of 
low malignant potential.
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Overall, 759 (90.7%) patients with new NMIBC were 
deemed by the surgeon to have had a complete initial 
PDD-TURBT; the remainder had incomplete resection, 
were managed with biopsy and fulguration or the com-
pleteness of resection was uncertain. The detrusor muscle 
was present in 581 (69.4%) NMIBC cases.
At early re-TURBT, residual disease was found in 27 
(13.0%) of 207 cases of high-grade NMIBC, with upstag-
ing to T2 cancer in three (1.5%) cases. Table 2 describes 
the association between primary tumour features and 
residual disease in patients with high-grade NMIBC, 
excluding those with CIS (n=167). Patients with multiple 
tumours, solid- or mixed-appearing tumours and T1 
tumours appeared more likely to have residual disease fol-
lowing complete PDD-TURBT for high-grade NMIBC 
compared to the historical control group.6 Residual cancer 
was found in 22 (17.6%) of 125 patients with the detrusor 
muscle present in the specimen and in eight (19.1%) of 42 
patients when the detrusor muscle was absent.
The overall RRFFC (including early re-TURBT for 
high-grade NMIBC) following complete PDD-TURBT 
was 8.9%. Table 3 describes RRFFC and recurrence rates 
at one year stratified by baseline recurrence risk groups.
Respective end points in the historical control group of 
patients undergoing GQ-WLTURBT are shown in Table 4.6
Discussion
This audit by the UK PDD Users Group has collected 
records from more than 1000 patients to date, providing 
the largest evidence base for HAL and for PDD in the UK, 
as well as being one of the largest patient pools globally. 
This collaboration represents the first multi-centre study in 
the UK to collect real-world data on recurrence/residual 
disease rates with HAL PDD.
In our study, RRFFC with PDD was 11%, the detrusor 
muscle was absent in only 31% of specimens and the resid-
ual disease rate was only 13% of high-grade NMIBC cases. 
Table 2. Univariate and multivariate regression analysis to determine association between primary tumour features and risk of 
residual disease following initial complete PDD-TURBT for high-grade NMIBC.
Variable Residual disease status, n (%) OR (95% CI), p
 Present Absent Univariate Multivariate
Tumour size Large (>3 cm) 11/69 (15.9) 58/69 (84.1) 1.2 (0.15–2.9), 0.7 –
 Small (⩽3 cm) 13/98 (13.3) 85/98 (86.7)  
Tumour number 1–2 8/104 (7.1) 96/104 (92.9) 4.1 (1.5–11.3), 0.001 3.1 (1.3–9.5), <0.01
 ⩾3 16/63 (25.4) 47/63 (74.6)  
Tumour appearance Papillary 15/128 (11.7) 113/128 (88.3) 2.3 (0.8–6.2), 0.07 –
 Solid or mixed 9/39 (23.1) 30/39 (76.9)  
Pathological stage pTa 7/75 (9.3) 68/75 (90.7) 2.2 (0.8–6.7), 0.1 –
pT1 17/92 (18.5) 75/92 (81.5)  
The analysis includes data from 167 patients, of whom 154 had re-TURBT and 13 had cystoscopy in three months; excludes patients with primary CIS.
PDD: photodynamic diagnosis; TURBT: transurethral resection of bladder tumours; OR: odds ratio; CI: confidence interval.
Table 3. Recurrence rates at first follow-up cystoscopy (RRFFC) and at one year (RR-1y).
RRFFC,a n/N (%) RR-1y, n/N (%)
Overall 85/801 (10.6) 41/225 (18.2)
After complete PDD-TURBT 65/730 (8.9) 38/209 (18.2)
By recurrence risk
 Low 7/185 (3.8) 3/63 (4.8)
 Intermediate 23/182 (12.6) 17/83 (20.5)
 High 25/171 (14.6) 17/75 (22.7)
aIncludes re-TURBT at two to six weeks for patients with high-grade disease and first follow-up visit at three months for patients with low- or 
intermediate-risk disease at the Edinburgh, Middlesbrough and Exeter centres.
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This is in line with the 11% residual disease rate observed 
with the use of advanced optical imaging tools in the study 
by Geavlete et al.10 and appears favourable in comparison 
to historical studies of early re-TURBT, where residual dis-
ease rates of up to 76%12,13 and rates of complete resection 
(including muscle) of 20–84%14–16 were observed.
This analysis is a single-arm audit, without a contempo-
rary control group. However, the results can be considered 
in light of experiences at one of the centres (Western General 
Hospital), which offers a historical control group of patients 
managed by experienced urologists who were also involved 
in the present audit. Despite the GQ-WLTURBT, the 
RRFFC was 31%, with 40.5% residual disease at early re-
TURBT in high-risk patients, and the detrusor muscle was 
absent in almost 40% of specimens.6
The reduction in residual disease and recurrence rates 
could be attributed to: the high level of experience of the 
surgeons performing TURBT; good-quality training, with 
overall improved attention to detail and close supervision; 
dedicated lists for TURBT at participating centres; includ-
ing the detrusor muscle in the specimen11,17; state-of-the-
art cystoscopes and video equipment; and use of advanced 
optical imaging tools such as PDD. In addition, the num-
ber of incorrectly staged patients was minimal (1.5% in 
our study compared to up to one third in historical TURBT 
series13,15,16). This means that appropriate treatment is ini-
tiated without delay.
With such potential to improve detection and resection 
with PDD in the majority of patients, we hypothesise that 
the number of cases requiring early re-TURBT could be 
substantially reduced, allowing resources to be prioritised 
in the subgroups most likely to benefit. One such subgroup 
is those with multifocal disease, which was found to be the 
most significant factor in increasing the residual disease 
rate. Another subgroup that could benefit is those where 
the muscle is absent from the specimen. Indeed, in a large 
multi-centre cohort, Gontero et al. found that re-TURBT 
had no impact on recurrence, progression, cancer-specific 
survival or overall survival in cases where the muscle was 
present in the initial resection specimen.18 This has been 
shown to be an indicator of high-quality resection.19 The 
use of PDD could potentially reduce the burden of repeat 
surgery and its possible complications, including the risk 
of tumour seeding and spread, in other patient subgroups 
such as those with large lesions or only one or two stage T1 
lesions.20 This approach would currently be at odds with 
international guidelines1,21 but, if validated by further 
research, could represent a new direction of travel to 
reduce the burden of NMIBC management on patients and 
health-care services.
We believe that we have provided an important founda-
tion on which to build a long-term evidence base for the 
use of HAL PDD in the management of NMIBC. Our aim 
in the future is to try to standardise prospectively collected 
information on each PDD case across centres, so that, in 
time, we can undertake high-quality analyses of consistent 
data from as large a pool of patients as possible. We 
encourage all centres using HAL PDD to join this initia-
tive, regardless of how much experience they currently 
have, as one of our aims is to show the increasing benefit 
of PDD over time, not just in terms of improving results 
versus WLC, but also because we believe that PDD can 
improve our surgical technique overall.
Limitations
The audit results that we present here come from both pro-
spectively and retrospectively collected data from different 
centres, with varying levels of experience using HAL PDD 
and with, in some cases, restrictions on the patients in 
whom HAL PDD is used. In addition, each centre initially 
set up its own methods of recording details for each patient. 
The heterogeneity of the data and limited information 
available for some of the factors that potentially influence 
Table 4. Outcomes after PDD-TURBT compared to findings in a control group of patients undergoing good-quality WL-TURBT at 
the Western General Hospital.6
PDD-TURBT, n (%) WL-TURBT,6 n (%) Univariate OR (95% CI), p
Patients with newly diagnosed NMIBC 837 302  
Complete initial TURBT 759 (90.7) 225 (74.5) 3.3 (2.4–4.7), 0.001
Detrusor muscle in specimen 581 (69.4) 187 (61.9) 1.4 (1.1–1.8), 0.02
Residual disease at early re-TURBT in patients 
with high-risk NMIBC
27/207 (13.0) 17/42 (40.5) 4.5 (2.2–9.5), <0.001
Upstaging after re-TURBT 3/207 (1.5) 2/44 (4.5) N/A (too small values)
Overall RRFFC 85/801 (10.6) 48/155 (31.0) 3.8 (2.5–5.7), <0.001
RRFFC in low-risk NMIBC 1/57 (0.02) 15/68 (22.1) N/A (too small values)
RRFFC in intermediate-risk NMIBC 7/69 (10.2) 16/47 (34.0) 4.6 (1.7–12.3), 0.002
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outcome need to be borne in mind when considering our 
results. For example, data on the use of mitomycin C are 
only available from the Edinburgh centre, where 74% of 
patients received a single mitomycin C instillation within 
24 hours of initial cystoscopy. Such challenges with data 
collection from multiple UK centres in relation to bladder 
cancer were also experienced in the BAUS radical cystec-
tomy audit, where only 37% of in the Hospital Episode 
Statistics data were entered into the database with signifi-
cant data heterogeneity.22
Conclusion
In conclusion, our audit data suggest the use of HAL PDD 
may improve bladder visualisation, thereby increasing the 
probability of complete resection and reducing the risk of 
recurrence. This was evident in this multi-centre audit across 
all risk groups, including those with high-grade or multifo-
cal tumours or CIS. Further high-quality, prospective data 
collection across UK centres is needed to confirm this.
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